IP Library › Granted Patent US 11,173,191
Granted Patent B2
US 11,173,191 · App. 16/444,807 · Granted Nov 16, 2021

IL-15-based molecules and methods of use thereof

Inventors: Bai Liu (Cooper City, FL); Peter Rhode (Miami, FL); Wenxin Xu (Pembroke Pines, FL); Hing C. Wong (Weston, FL)
Assignee: Altor Bioscience, LLC.
A61K38/2086A61K39/04A61K39/39558C07K14/5443C07K14/7155C07K16/2818C07K16/2827C07K16/2887C07K16/32C07K19/00C07K14/35C07K2317/732C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,173,191
App. No.
16/444,807
Granted
Nov 16, 2021
Kind
B2
Abstract

The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

Claims (8)

1. A method of treating cancer, comprising: administering to a human subject in need thereof i) an effective amount of Bacillus Calmette-Guerin (BCG) and ii) an effective amount of an IL-15N72D:IL-15RαSu/Fc complex.

2. The method of claim 1 wherein the subject has bladder cancer.

3. The method of claim 1 wherein the subject has non-muscle invasive bladder cancer (NMIBC).

4. The method of claim 1 wherein the subject has BCG-naive non-muscle invasive bladder cancer.

5. The method of claim 1 wherein the IL-15N72D:IL-15RαSu/Fc complex comprises a dimeric IL-15RαSu/Fc and two IL-15N72D molecules.

6. The method of claim 1 wherein ALT-803 is administered to the subject.

7. The method of claim 1 wherein ALT-803 in combination with BCG is administered by instillation into the bladder of the subject.

8. The method of claim 1 wherein the subject has been identified as suffering from non-muscle invasive bladder cancer (NMIBC).

Assignments (3)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2021
From: LIU, BAI; RHODE, PETER; XU, WENXIN; WONG, HING C.
To: ALTOR BIOSCIENCE CORPORATION
Reel/Frame 057346/0887 →
MERGER Recorded Aug 31, 2021
From: ALTOR BIOSCIENCE CORPORATION
To: ALTOR BIOSCIENCE LLC
Reel/Frame 057346/0896 →
Continuity (4)
Continuation 15921512 · Mar 14, 2018
Division 14755989 · Jun 30, 2015
Provisional Application 62018899 · Jun 30, 2014
Related Publication 20200016239A1 · Jan 16, 2020
Cited By (5)
US 12,186,372 US 12,268,731 US 12,268,732 US 12,318,432 US 12,371,472